Health Global News & Press Release Distribution

Health

All
APAC

Zepp Health Partners with Wild.AI to Offer Groundbreaking Women's Wellness App on Amazfit Smartwatches

-Enhancing women's health with advanced wearables with hormone and cycle tracking to unlock their full potential. MILPITAS, Calif., Aug. 15, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health") (NYSE: ZEPP), a global leader in smart wearables and health technology, together with Wild.AI,...

2024-08-15 21:00 1749

Xinhua Silk Road: Italy-based Salov, subsidiary of China's Bright Food Group, promotes olive oil culture through talent dev't programs

BEIJING, Aug. 15, 2024 /PRNewswire/ -- Salov SpA (Salov), an Italy-based edible oil producer that owns the globally recognized olive oil brands Filippo Berio and Sagra and was acquired byChina's Bright Food Group in 2015, has been advancing olive oil culture through talent development programs. ...

2024-08-15 15:54 1648

Xinhua Silk Road: Italy-based Salov, subsidiary of China's Bright Food Group, promotes olive oil culture through talent dev't programs

Ivonescimab (PD-1/VEGF) Received Priority Review from China's NMPA for First-Line Treatment of PD-L1 Positive NSCLC

The Second Indication of Ivonescimab in NSCLC 2L+ EGFRm NSCLC Already Approved in May 2024 HONG KONG, Aug. 14, 2024 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) ("Akeso,") today announced that the National Center for Drug Evaluation of the State Drug Administration ofthe People's Republic of China...

2024-08-15 07:30 1701

Qilian International Holding Group Ltd. Announces Trading Ticker Symbol to "BGM"

CHENGDU, China, Aug. 13, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ: QLI), aChina-based pharmaceutical and chemical products manufacturer, announced today that effective onAugust 11, 2024, its Class A ordinary shares will begin trading on the...

2024-08-13 20:00 2693

Celltrion USA announces incorporation of adalimumab-aaty, a Humira® biosimilar, to the Costco Member Prescription Program

* Adalimumab-aaty was first approved by the Food and Drug Administration on May 23, 2023 and became commercially available among key distributors across the U.S. onJuly 2, 2023 * Adalimumab-aaty's inclusion creates greater accessibility to treatments for Americans with inflammatory conditions...

2024-08-13 07:46 1599

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA

SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has been granted Breakthrough Therapy Designation (BTD) bythe Center for Drug Evaluation (CDE) of China's...

2024-08-12 22:00 1918

Momcozy's Ongoing Campaign for Breastfeeding Awareness Month Connects Moms and Breaks Barriers

NEW YORK, Aug. 12, 2024 /PRNewswire/ -- During Breastfeeding Awareness Month, global mother and baby brandMomcozy hosts a campaign to empower mothers and break down breastfeeding barriers. Fe...

2024-08-12 22:00 1208

Momcozy's Ongoing Campaign for Breastfeeding Awareness Month Connects Moms and Breaks Barriers

Xiao-I Corporation Showcases Hearview Smart Glasses at Successful U.S. Launch Event

SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- Xiao-I Corporation ("Xiao-I" or the "Company") (NASDAQ: AIXI), a leading artificial intelligence company, is proud to announce the successful U.S. launch of its innovative Hearview Smart Glasses. The event, which was streamed live on YouTube onAugust 8th at...

2024-08-12 21:30 2874

VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism

* 77.6% of patients treated with palopegteriparatide in the PaTHway China Trial achieved the primarymulti-component endpoint compared to 0.0% for placebo (p <0.0001) * Palopegteriparatide was generally safe and well-tolerated, with no discontinuations related to study drug. SHANGHAI, Aug. 12...

2024-08-12 21:00 1799

Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial

There was a clinically meaningful and persistent improvement depression measured by the key secondary endpoint of MADRS.[1] The primary endpoint of superiority to placebo in a cognitive "attention composite" of three Cogstate computerized tests was not met with large improvements seen in both Xan...

2024-08-12 20:30 1817

Milestone: Renal Nerve Mapping / Selective Renal Denervation (msRDN) System by SyMap Medical Ltd Approved for Treatment of Uncontrolled Hypertension in China

SUZHOU, China, Aug. 12, 2024 /PRNewswire/ -- On August 6, 2024, the msRDN System (SyMapCath I®/ SYMPIONEER S1®), developed by Suzhou/China-based SyMap Medical Ltd. (SyMap Medical), was approved by the National Medical Products Administration (NMPA) ofChina and granted a Class III Medical Devices ...

2024-08-12 13:55 1362

IASO Bio Receives U.S. FDA Approval of Investigational New Drug Application for Equecabtagene Autoleucel for Two New Autoimmune Disease Indications

SHANGHAI, NANJING, China and SAN JOSE, Calif., Aug. 12, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced that the investigation...

2024-08-12 13:52 1435

The San Ignacio Hospital project in Peru was officially handed over

BEIJING, Aug. 11, 2024 /PRNewswire/ -- On 1 August local time, the San Ignacio Hospital project inPeru, constructed by POWERCHINA, successfully passed the final acceptance of the owner and obtained the official handover certificate. This project is the first hospital project formally handed over ...

2024-08-12 10:55 2380

The San Ignacio Hospital project in Peru was officially handed over

GenScript Biotech Reports First Half 2024 Results

Strong Revenue Growth and Strategic Advances Across Key Segments, Enhances Commitment to ESG and Sustainable Development * Impressive Financial Growth: The group reported a 43.5% increase in revenue, driven by a 156% boost in cell therapy revenue and a 75.4% rise in gross profit, showcasing s...

2024-08-09 23:19 3744

Innovative Anti-Nausea Smartwatch EmeTerm® Smart Set to Launch on Indiegogo

VANCOUVER, BC, Aug. 8, 2024 /PRNewswire/ -- EmeTerm® Smart uses patented hybrid technology to seamlessly integrate the functionality of a smartwatch with that of an anti-nausea wristband, ensuring a carefree and healthy life for all. EmeTerm® Smart is launching on Indiegogo as the world's first a...

2024-08-08 23:00 1624

Innovative Anti-Nausea Smartwatch EmeTerm® Smart Set to Launch on Indiegogo

T-MAXIMUM PHARMACEUTICAL Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy Breakthrough for Solid Tumors

Summary * T-Maximum Pharmaceutical develops allogeneic CAR-T therapies with a unique CRISPR/Cas9 Gene-Editing platform for solid tumors, provide a solution of two major pain points, GvHD and HvG, aiming to revolutionize cancer. * MT027, the product of target B7H3 received US FDA orphan drug d...

2024-08-08 20:00 2164

WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers

* Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™ * Collaboration is a three-year and potentially multi-TCR p...

2024-08-08 16:00 1775

WestGene to Advance Clinical Trials Following Dual IND Approvals for World's First EB Virus-Related mRNA Therapeutic Cancer Vaccine

CHENGDU, China, Aug. 7, 2024 /PRNewswire/ -- WestGene Biopharma is proud to announce that its mRNA therapeutic cancer vaccine, WGc-043, has received dual IND approvals fromChina's National Medical Products Administration (NMPA) and the US FDA. This unprecedented achievement marks the world's firs...

2024-08-08 10:59 1539

WestGene to Advance Clinical Trials Following Dual IND Approvals for World's First EB Virus-Related mRNA Therapeutic Cancer Vaccine

Concord Medical Regains Compliance with NYSE Minimum Price Requirement

BEIJING, Aug. 7, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it has received a letter from the New York Stoc...

2024-08-07 20:30 3237

Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States

TAIPEI, Aug. 7, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has signed a non-binding terms agreement with Eyenovia, Inc. ("Eyenovia", NASDAQ: EYEN), whereby the companies will co-develop Clobetasol Propionate Ophthalmic Suspensi...

2024-08-07 20:00 2070

1 ... 16 17 181920 21 22 ... 280